

PROLIGHT DIAGNOSTICS SHOWS PROOF-OF-PERFORMANCE FOR HIGH-SENSITIVE IMMUNO ASSAY

Prolight Diagnostics (“Prolight”) today announced that its subsidiary Psyros Diagnostics (“Psyros”) has been able to demonstrate proof-of-performance that its high-sensitivity immunoassay is capable of reproducibly detecting low levels of specific proteins in a digital manner.

“This is a very important step on our journey to develop a high-sensitivity assay for digitally detecting troponin. Such an assay that is uniquely developed for point-of-care testing would be very valuable when detecting and diagnosing heart attack,” said Ulf Bladin, CEO of Prolight Diagnostics.

Using human plasma samples, thyroid stimulating hormone (TSH) levels were measured down to single digit nanogram per liter (ng/L) with laboratory grade reproducibility. These concentrations are indicative of those required for rule out of myocardial infarction using high-sensitivity troponin assays, in line with the European Cardiology Society’s Guidelines on Fourth Universal Definition of Myocardial Infarction.

“The impressive results mean that we are now ready to take the next step in developing our high-sensitive troponin assay. The speed at which we were able to reach this sensitivity and reliability with our first digital immunoassay, bodes well also for the development of many other assays in large indication areas,” said Ulf Bladin.

For further information, please contact:

Prolight Diagnostics AB (publ)

E-mail: ub@prolightdiagnostics.se

Telephone: +46 73 582 39 87

Website: www.prolightdiagnostics.se/en/

About Us

Prolight Diagnostics, together with the subsidiary Psyros Diagnostics and technology partners, develops innovative and flexible near-patient testing systems, Point-of-Care Testing (POCT), which is IT based on patented technology. POC tests are performed outside the traditional hospital laboratory with small mobile instruments in health centres, nursing homes, emergency departments, intensive care units, and other settings, enabling testing close to the patient and with rapid test results. With this technology, health care providers will be able to sort out patients in need of rapid treatment from patients that, for example, are not having a heart attack. The sales value in the POCT area amounted to USD 34.6 billion in 2021 and is growing strongly.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

This information is information that Prolight Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-11-29 08:00 CET.

Attachments

Prolight Diagnostics shows proof-of-performance for high-sensitive immuno assay